Airbus Launches Airspace Link HBCplus – The Flexible High Bandwidth Connectivity Solution for Airlines
14.6.2022 12:30:00 EEST | Business Wire | Press release
Airbus has launched Airspace Link HBCplus, its new flexible satellite connectivity solution that will be offered as an SFE* line-fit catalogue option and also for retrofit on all Airbus programmes. HBCplus, which initially encompasses Ka-band services, will enable airlines to connect to a choice of Managed Service Providers (MSPs) via a new certified terminal and radome built as part of the aircraft. In the future it is planned to extend HBCplus to include MSPs which offer Ku-band services.
Andre Schneider, Airbus VP Cabin & Cargo Programme said: “We are excited to offer airlines a new connectivity service solution that will provide improved speed and reliability for passenger experience and more flexibility. Together with our leading industry partners we are pleased to enable future connectivity business opportunities in the context of the Airspace Link open ecosystem.”
To this end Airbus has selected connectivity satcom leader Inmarsat as the first MSP, contributing its GX Aviation inflight broadband solution which offers reliable and seamless passenger experience with global coverage and capacity for future growth. Additional MSPs will join the HBCplus offering in due course.
Philippe Carette, President of Inmarsat Aviation, said: “We are honoured that Airbus has chosen Inmarsat as the first Managed Service Provider for this transformative connectivity catalogue solution and is putting its trust in our award-winning GX Aviation service across all of its aircraft programmes. Inmarsat looks forward to working closely with our partners Airbus and SPI to deliver continuous innovation for airlines and their passengers worldwide.”
Meanwhile Safran Passenger Innovations (SPI) has been selected as the terminal provider and hardware integrator of ThinKom’s proven antenna technology - targeted for Ka-band services which delivers high data throughput and reliability combined with aircraft fuel savings thanks to the antenna’s lower drag radome.
Matt Smith, CEO, Safran Passenger Innovations, said: “Safran Passenger Innovations is delighted to be selected as the equipment supplier for Airbus’ Airspace Link connectivity solution. We are excited to be a part of the next evolution in the IFC industry by providing the technology for airlines to select the connectivity services most suited to their needs. We look forward to working with Airbus and our partners on this industry-changing endeavour.”
Airspace Link HBCplus thus provides satcom based off-board connectivity for the Airspace Link open ecosystem representing an end-to-end Airbus offer. This solution, which enables the exchange of data as one seamlessly integrated aircraft system, is ideally positioned to unlock future digital services capacity and demand growth, allowing airlines to deliver a best in class passenger connectivity experience, in an exponentially growing market.
SFE* = Supplier Furnished Equipment
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220614005572/en/
Contact information
Martin FENDT
Airbus
+33 (0)6 29 54 27 03 martin.fendt@airbus.com
Lois BENQUET
Airbus
+33 (0)6 42 88 10 65 lois.benquet@arbus.com
Jared SIQUELAND
Safran Passenger Innovations
+1 714 203 0525 jared.siqueland@zii.aero
Robeel HAQ
Inmarsat Aviation
+44 (0)207 728 1352 robeel.haq@inmarsat.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces Positive CHMP Opinion for Opzelura ® (ruxolitinib) Cream for the Treatment of Adults with Moderate Atopic Dermatitis26.6.2026 14:30:00 EEST | Press release
Incyte (Nasdaq: INCY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the approval of Opzelura® (ruxolitinib) cream for the treatment of moderate atopic dermatitis (AD) in adult patients for whom topical corticosteroids (TCSs) and topical calcineurin inhibitors (TCIs) are inadequate or inappropriate. “AD is a chronic skin condition that can have a significant impact on daily life. The positive CHMP opinion for Opzelura marks meaningful progress toward bringing the first non-steroidal topical JAK treatment option to adults in Europe with moderate AD for whom standard topical therapies have failed,” said Lee Heeson, Executive Vice President and Head of Incyte International. “If approved by the European Commission, Opzelura could help address an important gap for patients who have limited treatment options when TCSs and TCIs are inadequate or inappropriate.” The positive CHMP o
Datroway ® Recommended for Approval in the EU by CHMP as First-Line Treatment for Patients with Metastatic Triple Negative Breast Cancer Who Are Not Candidates for Immunotherapy26.6.2026 14:00:00 EEST | Press release
Datroway® (datopotamab deruxtecan) has been recommended for approval in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the TROPION-Breast02phase 3 trial, which werepresented at the 2025 European Society for Medical Oncology Congress and published in Annals of Oncology. The recommendation will now be reviewed by the European Commission, which has the authority to grant marketing authorizations for medicines in the EU. In TROPION-Breast02, Datroway demonstrated a
DAYBU ® (trofinetide) Recommended for Approval in the European Union by CHMP26.6.2026 13:49:00 EEST | Press release
Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion following a re-examination procedure, recommending the granting of a marketing authorization for DAYBU® (trofinetide) for the treatment of neurobehavioral symptoms of Rett syndrome in adults and pediatric patients aged five years and older. If granted marketing authorization by the European Commission, DAYBU® would be the first therapy approved for this indication in the European Union (EU). “The CHMP’s positive opinion for DAYBU® is an important milestone in our mission to bring this innovative therapy to the EU, where there are no therapies specifically approved for the neurobehavioral symptoms of this devastating condition," said Catherine Owen Adams, Acadia’s Chief Executive Officer. “Our commitment is to make a meaningful difference in the lives of patients, caregivers, and the wider Rett com
HTEC Showcases Lakebase Branching at Databricks’ Data & AI Summit26.6.2026 12:18:00 EEST | Press release
HTEC, the global technology and AI engineering firm headquartered in Silicon Valley, last week showcased how it used Lakebase data branching to enable faster development, safer operations, and new possibilities for data-driven organizations operating in highly regulated environments. The Solution was developed in collaboration with a leading risk and compliance technology provider who serves financial institutions. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260626875859/en/ HTEC, the global technology and AI engineering firm headquartered in Silicon Valley, last week showcased how it used Lakebase data branching to enable faster development, safer operations, and new possibilities for data-driven organizations operating in highly regulated environments. Solving Critical Development Bottlenecks in Regulated Environments At the core of the collaboration was a shared challenge: how to enable modern data workflows in an envi
Stallergenes Greer Named One of Switzerland’s Best Managed Companies for 202626.6.2026 11:28:00 EEST | Press release
Stallergenes Greer, a global leader in allergy care, has been recognised for its overall business performance, company culture, and sustained growth by receiving the prestigious 2026 Switzerland’s Best Managed Companies award. The 2026 Best Managed Companies programme award winners are among Switzerland’s best private companies. The awards are derived from Deloitte’s global Best Managed Companies awards programme, an internationally recognised programme that evaluates businesses based on their leadership in the areas of strategy, culture and commitment, capabilities, innovation, governance and financial performance. Applicants are evaluated by an independent jury of experts. The evaluation of the Switzerland awards is based on more than 30 years of observed practice from the global awards programme that has been rolled out in 50+ countries worldwide. This recognition reflects Stallergenes Greer's consistent ability to deliver on its strategic vision while maintaining the operational di
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom